Introduction {#s1}
============

Development of solid organs is a dynamic process, but classical investigations of mammalian organogenesis have been limited largely to static analysis of fixed tissues. In the pancreas, epithelial cells form branched tubes that develop into exocrine acinar and ductal cells required for digestion. From that branching epithelium, endocrine progenitors differentiate and initiate cell shape changes culminating in delamination and outward migration into overlying mesenchyme. Subsequently, migrating endocrine cells differentiate into hormone-producing cells, including insulin^+^ and glucagon^+^ cells, that cluster to form morphologically distinct, vital structures called the islets of Langerhans, which regulate metabolism ([@B1]--[@B3]). Methods to visualize single cells developing along this endocrine lineage would advance our understanding of islet development.

Pancreatic endocrine precursor development is regulated by the basic helix-loop-helix transcription factor Neurogenin3 (Neurog3). Mice without *Neurog3* form a pancreas but have no islet cells, other than a small transient population of glucagon^+^ cells ([@B4]), and die perinatally with severe hyperglycemia and no detectable insulin production ([@B5]). Mice ectopically expressing *Neurog3* in early pancreatic progenitors divert cells toward an endocrine fate ([@B5]--[@B7]). These and other findings indicate that *Neurog3* is both necessary and sufficient for inducing pancreatic endocrine differentiation and establishing islet cell fate during mouse development ([@B8]--[@B13]). Humans with mutations in *NEUROG3* suffer from congenital diarrhea, caused by a deficit of intestinal endocrine cells, that is accompanied by a varying severity of insulin deficiency and diabetes ([@B14]--[@B16]). A subset of patient-derived *NEUROG3* alleles may be hypomorphic or null, based on assays in cell lines and nonmammalian systems ([@B17]). Puzzlingly, some patients with intestinal anendocrinosis and neonatal diabetes harboring suspected null *NEUROG3* alleles have low but detectable serum C-peptide, an indicator of insulin secretion, suggesting that NEUROG3-independent β-cell development may occur in humans ([@B14],[@B15]). Thus, developmentally relevant systems for testing gene function of human alleles of NEUROG3 are needed. In mice, *Neurog3* directly induces the expression of multiple targets, including genes encoding the transcription factors, *NeuroD1*, *Pax4*, *Insm1*, and *Rfx6* ([@B18]--[@B23]). Mouse mutants lacking each of those factors have distinct endocrine defects, suggesting that gene networks governed by *Neurog3* have multiple distinct phenotypic outputs ([@B24],[@B25]). Thus, simple methods for assessing the cellular and molecular functions of *Neurog3* and its targets in the developing pancreas could prove useful for decoding regulatory networks governing islet development.

During islet formation, studies of fixed tissues have provided evidence that *Neurog3* is required for initiation of islet formation, which includes epithelial cell deformation, delamination, outward movement, hormone expression, and clustering into polyclonal multicellular aggregates. However, control of these transient features of islet development by Neurog3 remains unclear, reflecting a lack of assays to quantify transient cellular phenotypes. Prior studies show that Neurog3^+^ cells lose polarized expression of markers including Mucin and aPKC; express *Snail2*, a transcriptional regulator of the epithelial-to-mesenchymal transition; and appear to exit the fetal pancreatic epithelium ([@B9],[@B26]). Hormone-expressing progeny derived from Neurog3^+^ endocrine progenitor cells are detected in fixed tissues both as single cells and as small clusters of multiple islet cells throughout development. As development progresses, these islet clusters enlarge and remodel to form mature islet morphology ([@B27]--[@B30]). Overexpression of *Neurog3* in an immortalized pancreatic ductal cell line altered expression of a subset of genes involved in cell migration and intercellular interactions, suggesting a role for Neurog3 in initiating transcriptional changes that promote migratory phenotypes ([@B31]). Prior important live-cell analysis in the developing mouse pancreas ([@B32]) permitted description on a multicellular scale of fetal epithelial branching and β-cell movement but did not image single cells from multiple cell populations simultaneously. Live imaging of differentiating pancreatic cells at such high resolution could reveal basic cellular aspects of development, permit single-cell analysis of phenotypes not measurable in fixed sections, and enhance studies of *Neurog3*-dependent phenotypes. Here, we present approaches to studying pancreas development that combine somatic gene alterations, mutant analysis, genetic complementation or suppression, live cell imaging, and single-cell analysis to assess the regulation of endocrine cell morphogenesis and differentiation in the developing pancreas.

Research Design and Methods {#s2}
===========================

Animals {#s3}
-------

All animal studies were performed in accordance with Stanford University Institutional Animal Care and Use Committee guidelines. Mouse *Insulin1* promoter--green fluorescent protein (GFP) transgenic mice were obtained from The Jackson Laboratory ([@B33]). *Neurog3^gfp^* knock-in mice were a gift from Klaus Kaestner (University of Pennsylvania) ([@B34]). NOD-SCID mice for transplantation experiments were purchased from The Jackson Laboratory.

The *Neurog3-tdTomato~mosaic~* transgenic line expresses tdTomato with a bovine growth hormone polyadenylation sequence under the control of a 6.5-kb fragment of the mouse *Neurog3* promoter. No growth hormone coding sequence is present in the transgene construct. The line was generated in the Stanford Transgenic Mouse Research Facility. After construct injection, 23 founders were obtained and were crossed to CD1 females; two lines were maintained. The line reported here exhibits mosaic expression, whereas the transgene reported previously ([@B35]) is expressed in all Neurog3-positive cells. Genotyping was performed using primers to detect the Tomato coding sequence.

For growth of human pancreatic tissue in the renal subcapsular space, NOD-SCID mice were anesthetized with ketamine/xylazine and tissue was transplanted into the left renal capsule. Kidneys were harvested after 2 weeks for histological analysis.

Immunofluorescence and RNA Analysis {#s4}
-----------------------------------

Tissue was fixed in 4% paraformaldehyde and embedded in optimal cutting temperature for cryosectioning. Sections (10 μm) were prepared for immunofluorescence analysis. Primary antibodies used are indicated in [Table 1](#T1){ref-type="table"}. Alexa-Fluor--conjugated secondary antibodies (Life Technologies and Jackson Immunoresearch) were used for detection.

###### 

Antibodies used in this study

  Antigen and host                                    Source                 Dilution
  --------------------------------------------------- ---------------------- ----------
  Neurog3, rabbit polyclonal                          Seung Kim Laboratory   1:500
  Insulin, guinea pig polyclonal                      Sigma                  1:500
  Glucagon, guinea pig polyclonal                     Linco                  1:500
  Chromogranin A, rabbit polyclonal                   Immunostar             1:500
  Mucin, hamster monoclonal                           Neomarkers             1:250
  Carboxypeptidase A1, rabbit polyclonal              Chemicon               1:1,000
  Dolichos biflorus agglutinin lectin, biotinylated   Vector Laboratories    1:1,000
  GFP, chicken polyclonal                             Abcam                  1:500

RNA was purified from organ cultures using the standard TRIzol protocol (Invitrogen). cDNA was synthesized using the RetroScript kit (Ambion) and was analyzed by quantitative PCR with commercially available TaqMan probes (Applied Biosystems) for genes indicated in the text. Analysis of sorted cell populations by FACS was performed as previously described using transgenes indicated in the text ([@B36]). Adenovirally expressed human *NEUROG3* was detected using custom TaqMan probes: 6-FAM/CTGGGAAGGTGGGCAGGACA/TAMRA-Sp (probe), CTCAACTCGGCACTGGAC (primer), and AGATGTAGTTGTGGGCGAAG (primer). Expression levels were normalized to *ActB*, and results were shown as levels relative to control samples indicated in the text. At least three independent organs were analyzed for each condition.

Organ Culture and Imaging {#s5}
-------------------------

Fetal pancreata were dissected on ice from mice at embryonic day (E) 13.5 for culture and imaging. Epithelium and mesenchyme from dorsal and ventral remained visibly intact. Organ rudiments were visually screened for the expression of *Ins1*-GFP, *Neurog3*-tdTomato~m~, or *Neurog3^gfp^* alleles with a Leica epifluorescence dissecting microscope. *Neurog3^gfp/gfp^* organs were distinguished from *Neurog3^gfp/+^* organs visually by morphology and GFP intensity. Genotypes were confirmed retrospectively by PCR for the presence of GFP and the wild-type *Neurog3* allele.

After dissection, organ rudiments were transferred to a chambered cover slip (Nunc Laboratory-Tek) or a 60-mm tissue culture dish and embedded in type 1 collagen gel (Wako). Organs were cultured in phenol red-free DMEM/F12 (Invitrogen) supplemented with 10% FBS (HyClone), 1% penicillin streptomycin, and 1% insulin/transferrin/selenium (Sigma). Media was refreshed every 2 days of culture. Vascular labeling was accomplished by injecting fluorescein isothiocyanate--conjugated *Lycopersicum esculentum* lectin (Vector Laboratories) into the umbilical vein of the E13.5 fetus before separation from the placenta.

Imaging was performed using Zeiss LSM510 and Leica SP5 confocal microscopes with ×20 water-immersion objectives and environmental-control chambers to maintain an imaging environment at 37°C with 5% CO~2~. Images were acquired at 1,024 × 1,024 resolution with 4 μm separating Z sections and 20 min separating Z-stack acquisitions. Data were saved in LSM (Zeiss) or LIF (Leica) formats. ImageJ (National Institutes of Health) or Volocity (PerkinElmer) was used to compile Z stacks into XYT datasets, which were exported in TIFF format for analysis or AVI and MOV formats for viewing.

Analysis of Imaging Data {#s6}
------------------------

Movies were analyzed in ImageJ. For cell shape analysis, individual cells were manually traced and shape factor was calculated at each time point using the "Circularity" function. Shape factor = 4π(area)/(perimeter^2^). Cell shape traces over time were manually generated in ImageJ and analyzed using Microsoft Excel. Shape factor of single cells was traced from the first time point at which a cell was clearly detected until the last time point at which it could be distinguished from other cells. Simple averaging of single-cell shape traces did not indicate a stereotyped pattern of deformation for either *Neurog3*-tdTomato or *Ins1*-GFP cells. Normalization to the mean shape factor of an epithelial cell (E-cadherin^high^ pancreatic epithelial cells) followed by integration of the single-cell shape factor curve generated a plot of single-cell accumulated shape factor over time, a measure of a single cell's accumulated deviation from epithelioid shape. This path-independent measure of deformation allowed measurement of cell deformation undergone over time by defined cell populations. For statistical comparisons, area under the curve was computed for each individual sample, and biological groups were compared using a *t* test.

Clustering was analyzed by computing mean object size at each time point using the "Analyze Particles" function in ImageJ ([@B32]). Clustering values were normalized to the value calculated at *t* = 0 and plotted over time. Data were analyzed in Microsoft Excel.

GFP^high^ cells in *Neurog3^gfp/+^*, *Neurog3^gfp/gfp^*, and Ad-*NEUROG3* rescues were counted from Z stacks 50--70 μm thick acquired at single time points at the beginning of live imaging data sets. At least three organs per condition were analyzed.

Human Tissue {#s7}
------------

Experiments involving use of human tissue were approved by the Stanford University Institutional Review Board. Human pancreatic tissue between gestational days 76 and 110 was obtained through the Birth Defects Research Laboratory, University of Washington (Seattle, WA), and all donors provided informed consent.

Identification of Human NEUROG3^P39X^ Mutation {#s8}
----------------------------------------------

The study protocol was approved by the University of California, Los Angeles, institutional review board, and pertinent medical history, pathology, and DNA samples were obtained from the subject. The subject presented clinically with severe malabsorptive diarrhea as a neonate, and like others with enteric anendocrinosis was managed with parenteral nutrition ([@B16]). At 3 years of age, diabetes was diagnosed, and a C-peptide level of 3.6 ng/mL was measured (M.G.M., unpublished data). An Oragene saliva kit was used to obtain DNA, and exon 2 of NEUROG3 was PCR amplified and sequenced using oligonucleotides (5′CAATCGAATGCACGACCTCAAC-3′ \[sense\] and 5′-AGATTATGGGGTGGTGGCAGAG-3′ \[antisense\]). Sequencing revealed a homozygous single base deletion in codon 39 (c.117delC; p.P39PfsX38), leading to a frame-shift mutation and 38 additional amino acids that are out of frame prior to a premature transcriptional termination sequence (M.G.M., unpublished data).

Adenovirus Construction {#s9}
-----------------------

Adenoviruses were generated by cloning cDNAs of interest into the pDual-RFP-CCM or pDual-H2B:mCherry shuttle vectors, which express a fluorescent protein and the gene of interest under the control of separate cytomegalovirus promoters. The pDual-H2B:mCherry vector was constructed by amplification of the H2B:mCherry cDNA sequence by PCR from pcDNA3-H2B:mCherry (Addgene Plasmid 20972) and replacing the red fluorescent protein (RFP) sequence in pDual-RFP (Vector Biolabs, Philadelphia, PA). Custom high-titer adenoviruses (≥1 × 10^10^ plaque-forming units/mL) were generated by Vector Biolabs for all viruses except Ad-NEUROD1 and Ad-PAX6, which were purchased premade from Vector Biolabs. All adenovirus work was performed in compliance with regulations from the Stanford University Administrative Panel on Biosafety.

Adenovirus Microinjection {#s10}
-------------------------

Pancreatic rudiments were dissected from E13.5 embryos, preserving both dorsal and ventral pancreatic epithelia and mesenchyme. Intact pancreas rudiments were separated from surrounding intestinal and vascular structures. Organs were embedded in Type 1 Collagen gel (see above), and gel was allowed to polymerize for 1 h at 37°C before overlaying with cell culture media. Organs were incubated at 37°C for at least 1 h before beginning the injection procedure.

For injections, needles were produced by pulling 25 μL glass microcapillary tubes (no filament, cat. no. 53432-761; VWR) using a Flaming/Brown micropipette puller (model P-87; Sutter Instrument Co.) with the following settings: pressure 400, heat 580, pull 75, velocity 60, time 100. Needles were mounted on a brass straight-arm needle holder (MINJ-4; Tritech Research) attached to a standard manual control micromanipulator (640056; Harvard Apparatus). For preparation of needles, tips were broken with forceps, and viral solution (1 × 10^6^ plaque-forming units/μL) was loaded by drawing into the needle through the tip. A syringe and tubing filled with mineral oil were used to control pressure for delivery of the injection solutions.

Cultured pancreatic rudiments were visualized under a stereomicroscope, and epithelial structures were visually distinguished from mesenchyme: mesenchyme appears opaque under reflected light illumination, whereas epithelial structures appear translucent. Less than 2 μL virus solution was injected into the epithelium: larger volumes caused distension of the organ and could rupture the tissue. Efficiency of labeling could be increased by entering the epithelium at multiple locations throughout the dorsal and ventral pancreas, but doing so increased the risk of transducing nonepithelial cells. Injection solution was delivered slowly to minimize distension of the epithelial network. Viral labeling of pancreatic epithelial cells occurred in essentially all organs attempted, and epithelial restriction occurred in \>80% of rudiments (*n* \> 100). Fluorescence from a cytomegalovirus-RFP reporter transgene was detectable by the day after injection and increased through at least 5 days of culture. Addition of adenovirus only to the organ culture media, without injection, primarily resulted in infection of mesenchymal cells along the surface of the organ (data not shown).

Statistical Analysis {#s11}
--------------------

A two-tailed Student *t* test was used for statistical comparisons of gene expression, cell counts, and live-cell phenotypes. *P* values \<0.05 were considered significant. Data are presented as means ± SEM.

Results {#s12}
=======

Restoration of Islet Development in Neurog3 Mutants by Targeted Gene Transduction {#s13}
---------------------------------------------------------------------------------

Assessment of pancreas developmental genetics, especially transcriptional regulators of epithelial development, could be advanced by tests of gene function in a developmentally relevant context. For example, such assays could permit complementation or suppression analysis. To achieve this goal, we tested whether *Neurog3* mutant phenotypes could be rescued by exploiting the accessibility of pancreatic epithelium to microinjection in organ cultures. We embedded E13.5 organs in collagen gel and overlaid with culture media ([@B37]). Over 5 days of culture, we observed substantial growth and multilineage differentiation. After identifying the fetal pancreatic duct, we injected recombinant adenoviral vectors expressing a transgene encoding RFP (mRFP) into the lumen of cultured *Neurog3^gfp/gfp^* pancreatic rudiments ([Fig. 1*A*](#F1){ref-type="fig"}). The *Neurog3^gfp^* allele replaces the coding sequence of *Neurog3* with GFP, creating a null allele ([@B34]). The viral injection solution appeared restricted to the ductal epithelial tree. Consistent with this, immunostaining of rudiments after 5 days of culture showed that expression of mRFP was predominantly restricted to pancreatic epithelial cells ([Fig. 1*B* and *C*](#F1){ref-type="fig"}). Quantification revealed that 31 ± 4% of pancreatic E-cadherin^+^ epithelial cells coexpressed RFP, indicating a high efficiency of infection and gene transduction (*n* = 4) ([Fig. 1*B* and *C*](#F1){ref-type="fig"}). Thus, genetic transduction of fetal pancreatic epithelium was feasible in our system.

![Transduction of *Neurog3* mutant fetal pancreatic cells with human *NEUROG3* by adenovirus microinjection restores islet differentiation and morphogenesis. *A*--*C*: Microinjection of adenovirus into the fetal pancreatic epithelium permits transduction of epithelial cells. *D*: Rescue of islet-specific gene expression in *Neurog3^gfp/gfp^* organ rudiments by expression of wild-type human *NEUROG3* and assessment of enteric anendocrinosis patient-derived allele function. *E*: Histological evidence of islet differentiation and morphogenesis. Ad-*NEUROG3* efficiently restores islet gene expression and formation of islet cell clusters. The R107S patient allele restores a limited amount of differentiation, consistent with hypomorphic function. P39X and N89D (RFP) alleles fail to induce any changes in islet gene expression or morphogenesis, consistent with complete lack of function. Gene expression measurements were normalized to control *Neurog3^gfp/+^*;Ad-RFP cDNA. \**P* \< 0.05, Student *t* test.](db150042f1){#F1}

To assess the capacity for genetic complementation, we next injected homozygous mutant *Neurog3^gfp/gfp^* rudiments with adenovirus coexpressing wild-type human *NEUROG3* and RFP or control virus expressing RFP alone. Human mouse Neurog3 share 75% identity at the protein level. At baseline, *Neurog3* mutants fail to form islet cells, express markers of islet differentiation, or form islet-like cell clusters ([@B5],[@B6]), phenotypes recapitulated in our organ cultures (see below). In addition, GFP expression is very low in *Neurog3^gfp/gfp^* organs relative to *Neurog3^gfp/+^* controls, likely reflecting a lack of positive autoregulation in *Neurog3*-null pancreata ([@B38]). After transduction with wild-type *NEUROG3*, quantitative PCR (qPCR) analysis revealed that *NEUROG3* rescue resulted in a significant restoration of islet markers, with expression of Neurog3 target genes comparable with *Neurog3^gfp/+^* controls ([Fig. 1*D*](#F1){ref-type="fig"} and [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). For example, we observed restored expression of several direct targets of *Neurog3,* including *NeuroD1* and *Rfx6,* as well as expression of genes encoding islet hormones, including *Ins2* and *Gcg* ([Fig. 1*D*](#F1){ref-type="fig"}). Expression levels of Neurog3 target genes approached levels in *Neurog3^gfp/+^* littermates but did not reach those observed in *Neurog3^+/+^* controls, indicating that the level of *NEUROG3* rescue was partial ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). *Pdx1*, a gene expressed independently of *Neurog3* in pancreatic epithelial progenitors, remained unchanged as expected. Immunostaining of *Neurog3^gfp/gfp^* organs injected with Ad-*NEUROG3* confirmed restoration of insulin and glucagon protein expression and demonstrated the formation of large endocrine cell clusters resembling control islets ([Fig. 1*E*](#F1){ref-type="fig"}). We also observed a marked increase in GFP intensity, expressed from the endogenous *Neurog3* locus, throughout *Neurog3^gfp/gfp^* organ rudiments injected with Ad-*NEUROG3* ([Fig. 1*E*](#F1){ref-type="fig"}) (see below), consistent with NEUROG3 autoregulatory activity ([@B38]). In control *Neurog3^gfp/+^* organs injected with Ad-RFP, we observed 220 ± 27 GFP^high^ cells per field, while in *Neurog3^gfp/gfp^*;Ad-RFP control organs we observed only 6 ± 1 GFP^high^ cells per field (*P* = 0.001) ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). (See [[research design and methods]{.smallcaps}](#s2){ref-type="sec"}.) Thus, infection with virus, per se, did not induce GFP expression. Expression of wild-type *NEUROG3* restored GFP^high^ cell counts to 212 ± 17 cells per field in *Neurog3^gfp/gfp^* (*P* = 0.001 relative to *Neurog3^gfp/gfp^*, *P* = 0.52 relative to *Neurog3^gfp/+^*). These findings provide additional unique evidence that *NEUROG3* is capable of positive autoregulation ([@B38]). All rescued cells, as indicated by elevated GFP expression or expression of islet markers including ChgA, also coexpressed the RFP reporter, suggesting that the rescue observed was cell autonomous ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). In summary, our organ culture and microinjection system revealed the capacity for genetic complementation studies in mouse *Neurog3* mutant pancreata.

Complementation Analysis of Human NEUROG3 Alleles {#s14}
-------------------------------------------------

Mutations in *NEUROG3* have been linked to human congenital diarrhea and intestinal anendocrinosis with diabetes of variable onset and severity ([@B14]--[@B16]). It remains unclear, however, whether diabetes severity reflects a range of allele strength because current methods used to test *NEUROG3* alleles rely on in vitro cell line assays or ectopic expression in prepancreatic endoderm of nonmammalian model organisms. These systems may not recapitulate the appropriate pancreatic developmental context and do not yet permit analysis of dynamic phenotypes regulated by NEUROG3.

To test the function of three mutant human *NEUROG3* alleles in native fetal pancreatic epithelial cells, we microinjected adenoviruses into the *Neurog3^gfp/gfp^* epithelium and cultured organs for 5 days, assaying the ability of each allele to restore endocrine gene expression and features of islet morphogenesis. We tested the *NEUROG3^R107S^* patient allele ([@B16]), the synthetic null mutant *NEUROG3^N89D^* ([@B17]), and *NEUROG3^P39X^*, a new patient-derived allele (M.G.M., unpublished observations). qPCR probes that recognize wild-type and mutant forms of *NEUROG3* revealed comparable levels of corresponding transgenic *NEUROG3* mRNA after infection ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Expression of *NEUROG3^R107S^* restored GFP^high^ expression in a significant fraction of cells (48 ± 5 cells per field, *P =* 0.001 compared with 6 ± 1 in Ad-RFP control, [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Consistent with this finding, we also observed that expression of mRNAs encoding pancreatic endocrine factors and hormones was partially restored by *NEUROG3^R107S^* ([Fig. 1*D*](#F1){ref-type="fig"}). Hormone production was also detected by immunohistology in rudiments rescued by *NEUROG3^R107S^* ([Fig. 1*E*](#F1){ref-type="fig"}). By contrast, we detected no increase in GFP fluorescence after delivery of the *NEUROG3* P39X allele compared with Ad-RFP and Ad-N89D negative controls (7 ± 1 vs. 6 ± 1 cells per field, *P =* 0.29 compared with Ad-RFP control, [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Together these data support prior studies suggesting that *NEUROG3^R107S^* is a hypomorphic allele ([@B17]) and provide evidence that *NEUROG3^P39X^* is a null allele.

We postulated that our gene transduction system based on organ culture and subsequent analysis could be adapted to study human fetal pancreas development. We developed a sequential strategy for microinjection of adenoviral vectors into the ductal lumen of human fetal pancreatic tissue to modify gene expression, followed by transplantation in *NOD-SCID* mice to permit vascularization and development ([@B39],[@B40]). We then tested whether misexpression of *NEUROG3* was sufficient to induce endocrine differentiation in developing human pancreatic tissue. All adenoviruses coexpressed RFP under control of a second promoter to permit identification of transduced cells. Upon misexpression of wild-type *NEUROG3*, we observed clear induction of the "pan-endocrine" marker protein Chromogranin A (CHGA) within many transduced cells and establishment of large RFP-expressing cell clusters ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). CHGA expression was observed in 67 ± 2% of cells overexpressing wild-type NEUROG3. In contrast, we observed CHGA expression in only 12 ± 3% of RFP^+^ transduced cells in organs infected with the control *NEUROG3^N89D^* mutant, which lacks DNA-binding activity (*P =* 1.3 × 10^−4^, *n* = 3) ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Thus, *NEUROG3* misexpression was sufficient to direct endocrine differentiation and to promote islet cell cluster formation in developing human pancreatic cells.

Genetic Suppression of Neurog3 Mutant Phenotypes {#s15}
------------------------------------------------

Classical mutant suppression analysis can reveal or clarify functions of genetic regulators but to our knowledge has not previously been achieved with pancreas developmental mutants. Targets of *Neurog3* include *NeuroD1*, *Rfx6*, and *Pax4* ([@B18],[@B19],[@B22],[@B23]). We used adenoviral vectors to express human orthologs of these factors or the islet transcriptional regulator *PAX6* to assess their ability to suppress phenotypes in *Neurog3^gfp/gfp^* mutant rudiments.

We observed that *NEUROD1* overexpression partially restored expression of mRNA encoding chromogranin A and islet hormones compared with undetectable expression in controls infected with Ad-RFP ([Fig. 2*A*](#F2){ref-type="fig"}). Moreover, we observed ChgA protein expression by GFP^high^ cells in small clusters adjacent to major ductal structures ([Fig. 2*B* and *C*](#F2){ref-type="fig"}). Restoration of hormone and ChgA mRNA expression in these studies indicates successful suppression or bypass of the *Neurog3* mutation, although the magnitude of effect was less than that achieved by *NEUROG3* complementation. By contrast, genetic suppression of *Neurog3^gfp/gfp^* pancreas development using other transcriptional regulators was less robust. Ad-RFX6 infection led to a small but significant induction of *ChgA* (5.7% of control; *P* = 0.03) ([Fig. 2*A*](#F2){ref-type="fig"}) but not other markers of islet development. *PAX6* significantly induced mRNA encoding glucagon (*P =* 2 × 10^−8^) ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)) but not other markers, consistent with known roles for Pax6 in activating α-cell--specific gene expression and α-cell differentiation ([@B41]--[@B43]). Infection with adenovirus encoding *Pax4* resulted in no detectable changes of mRNA levels relative to Ad-RFP controls for genes including all islet hormones, *Neurod1*, *and ChgA* ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). In combination, *NEUROD1* and *RFX6* induced both *ChgA* and *Ghrelin* mRNA to levels greater than achieved by *NEUROD1* alone ([Fig. 2*A*](#F2){ref-type="fig"} and [Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)) (*P =* 9 × 10^−4^ and *P =* 0.03, respectively) and generated small multicellular clusters that expressed ChgA protein. Multiple other factors or combinations did not result in additional restoration of islet differentiation ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Together, these data suggest that *RFX6* and *NEUROD1* may collaborate to induce endocrine differentiation and islet cell aggregation without *NEUROG3*. Collectively, these results also show that genetic suppression analysis is feasible in our system.

![Suppression of *Neurog3^gfp/gfp^* phenotypes by downstream targets of *NEUROG3*. *A*: Injection of *Neurog3^gfp/gfp^* fetal pancreatic epithelia with adenoviruses carrying single and combinations of factors partially restores expression of markers of endocrine differentiation. Expression of *NEUROD1* induced small increases in expression of all hormones and of *ChgA*. Expression of *RFX6* alone caused small but significant increases in *ChgA* expression. Combination of *NEUROD1* and *RFX6* induced expression of *Ghrelin* (see [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)) and *ChgA* but not expression of other hormones. *B*--*E*: Histological analysis of organs injected with factors downstream of *NEUROG3* reveals ChgA-expressing cells as singlets or small clusters exiting the pancreatic epithelium in *Neurog3^gfp/gfp^*;Ad-NEUROD1 organs and fails to show any ChgA protein expression in *Neurog3^gfp/gfp^*;Ad-RFX6 organs. Organs transduced with *RFX6* and *NEUROD1* viruses in combination formed small clusters of ChgA-expressing cells separated from the epithelium. Scale bars: 25 μm. Gene expression measurements were normalized to *Neurog3^gfp/+^*;Ad-RFP controls. \**P* \< 0.05, Student *t* test.](db150042f2){#F2}

Two-Color Live Imaging at Single-Cell Resolution Reveals Cell Movement, Deformation, Differentiation, and Morphogenesis by Developing Fetal Pancreatic Cells {#s16}
------------------------------------------------------------------------------------------------------------------------------------------------------------

Tools to study living islet precursors at single-cell resolution could enhance studies of islet development, including assessment of *Neurog3* gene functions. To image and assess distinct live cell types in pancreas development, including our genetic complementation studies, we first labeled endocrine precursor cells by generating transgenic mice expressing the RFP tdTomato ([@B44]) under the control of a 6.5-kb fragment of the mouse *Neurog3* promoter ([@B35]). Immunostaining and FACS purification of pancreatic cells from this *Neurog3-*tdTomato transgenic line confirmed tdTomato labeling in fetal *Neurog3-*expressing pancreatic cells ([Supplementary Fig. 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Because of the perdurance of tdTomato labeling, we observed tdTomato expression in differentiated hormone^+^ islet cell progeny of *Neurog3-*expressing cells ([Supplementary Fig. 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). FACS and immunofluorescence analysis demonstrated that tdTomato transgene expression was mosaic in the mouse line used for these studies, labeling approximately half the *Neurog3*-expressing pancreatic cells marked by a *Neurog3*^*gfp*^ knock-in allele ([@B34]). This level of mosaicism facilitated subsequent single-cell tracking (see below) and distinguishes this line from one without mosaicism previously reported by our group ([@B35]). To label both endocrine precursors and hormone-expressing β-cells, we bred *Neurog3-*tdTomato mice with *Insulin1-*GFP transgenic mice ([@B33]). Resulting bitransgenic *Neurog3-*tdTomato*;Ins1-*GFP embryos enabled simultaneous labeling and tracking of *Neurog3-*expressing endocrine precursors and nascent fetal insulin-expressing β-cells in the same cultured pancreas rudiments. Thus, *Neurog3-*tdTomato transgenic mice provide a tool for analyzing a subset of living endocrine progenitor cells.

Islet cell differentiation and morphogenesis after birth of *Neurog3*^+^ cells requires several days; thus, to permit imaging experiments of sufficient duration, we next established a stable system for fetal pancreatic culture, development, and growth that minimized artifactual tissue movement. We used the same collagen-embedded organ culture scheme described above for rescue experiments, in which growth and differentiation occur as assessed by histology and qPCR ([Supplementary Figs. 5 and 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Immunohistology also revealed islet cell clustering after 5 days of culture ([Supplementary Fig. 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Thus, multiple criteria indicated that development of the three major cell lineages in the fetal pancreas occurred and that fundamental features of islet morphogenesis were reproduced in this culture system. To establish that our frame of reference for live imaging was stable, we labeled the vasculature by injecting fluorescein isothiocyanate--conjugated tomato lectin through the umbilical vein of mice prior to pancreas extraction; imaging of cells relative to the static vascular "reference" label indicated that our imaging field was stable ([Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1) and [Supplementary Movie 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). To confirm that we analyzed single cells, we labeled nuclei with a histone*H2B:GFP* transgene ([@B45]) and endocrine precursors with *Neurog3-tdTomato* and calculated the mean two-dimensional area of single cells. We used that area, 104 ± 7 μm^2^, as a reference during our analysis to identify single cells for tracking ([Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)).

A wave of pancreatic endocrine differentiation begins in fetal mice at approximately E13.5 ([@B1]). Thus, we cultured organs isolated at E13.5 and imaged at 20-min time intervals for 48 h to assess islet cell dynamics. Live imaging revealed several phenotypes in pancreata of *Neurog3-*tdTomato*;Ins1-*GFP mice ([Fig. 3*A--D*](#F3){ref-type="fig"} and [Supplementary Movie 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). We directly observed differentiation of individual red *Neurog3-*tdTomato^+^ endocrine precursor cells, as they initiated expression of *Ins1-*GFP and became progressively yellow and then green ([Fig. 3*E--H*](#F3){ref-type="fig"}). Not all *Neurog3*-tdTomato--expressing cells generated *Ins1-*GFP--expressing cells during our time-lapse studies, consistent with prior studies showing that *Neurog3^+^* cells generate β-cells and non-β-cells and with immunostaining data indicating that Tomato^+^ cells also expressed glucagon or insulin after organ culture experiments ([Supplementary Fig. 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Moreover, not all *Ins1-*GFP cells were derived from *Neurog3*-tdTomato^+^ cells, consistent with transgene mosaicism in this line. Second, we observed movement of *Neurog3-*tdTomato^+^ and *Ins1-*GFP*^+^* single cells into multicellular clusters ([Fig. 3*A--D*](#F3){ref-type="fig"} and [Supplementary Movie 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). At the end of time-lapse imaging, green *Ins1-*GFP^+^ multicellular clusters were a dominant feature. Thus, our studies permitted observation of endocrine differentiation and multicellular morphogenesis in living tissue at single-cell resolution. Third, imaging revealed that *Neurog3-tdTomato* and *Ins1-GFP* cells achieved often-dramatic morphological deformation, involving extension and retraction of cellular processes resembling filopodia, while moving into multicellular nascent islets ([Fig. 3*I--L*](#F3){ref-type="fig"}). For example, in some cases, cells extended processes up to three times longer than the cell body diameter ([Fig. 3*I--L*](#F3){ref-type="fig"}), a degree of deformation not previously reported to our knowledge. Thus, we have developed an organ culture and imaging system enabling discovery and measurement of dynamic cellular phenotypes during pancreatic endocrine differentiation and islet development.

![Time-lapse confocal microscopy of developing islet cells reveals dynamic single-cell phenotypes. Endocrine precursors at E13.5 were labeled with a mosaic *Neurog3-*tdTomato transgene, and insulin-expressing cells were labeled with an *Insulin1-*GFP transgene. Cell movement and deformation are visible in both populations, and clustering and differentiation of β-cells are observed throughout the movie. *A*--*D*: Frames from a 48-h movie. *E*--*H*: Single Neurog3-tdTomato--expressing cells differentiate into β-cells, initiating expression of the *Ins1-*GFP transgene. *I*--*L*: Extensive cell deformation and extension of processes are observed during cell movement and clustering. Scale bars: 200 μm (*A*--*D*) and 25 μm (*E*--*L*).](db150042f3){#F3}

Quantitative Analysis of Live-Cell Phenotypes in Pancreas Development {#s17}
---------------------------------------------------------------------

The single-cell resolution afforded by our live imaging system permitted quantification of dynamic cellular phenotypes like shape changes, movement, and clustering during endocrine differentiation. To quantify cell deformation, we calculated the shape factor of cells, which relates cell perimeter and area. A shape factor of zero corresponds to a straight line, whereas a shape factor of 1.0 corresponds to a perfect circle ([Fig. 4*A* and *B*](#F4){ref-type="fig"}). We found that the mean shape factor of a fetal pancreatic ductal epithelial cell after immunostaining with an E-cadherin antibody (see [[research design and methods]{.smallcaps}](#s2){ref-type="sec"}) was 0.83 ± 0.01 ([Supplementary Fig. 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Prior studies have applied shape factor measurements to analyze cell shape in islet development but relied on single or instantaneous measurements, which may obscure dynamic single-cell phenotypes over time ([@B46],[@B47]). We took advantage of our ability to track single cells over many hours of development and integrated the accumulated deformation of a cell over time. Tracking the shape factor of single cells during our time-lapse studies yielded continuous single-cell shape traces ([Fig. 4*A* and *B*](#F4){ref-type="fig"}, green line). We normalized to epithelial shape, integrated shape factor curves with respect to time, and calculated the accumulated deviation from epithelioid shape of individual *Neurog3-*tdTomato*^+^* cells and motile *Ins1-*GFP*^+^* cells not yet merged with islets ([Fig. 4*A* and *B*](#F4){ref-type="fig"}, blue line). We observed no significant difference in the shape factor between *Neurog3-*tdTomato*^+^* and *Ins1-*GFP*^+^* cells (*P =* 0.61) ([Fig. 4*C*](#F4){ref-type="fig"}). This similarity of cumulative cell shape changes is therefore consistent with our observation that differentiating pancreatic endocrine cells begin deformation and movement at the *Neurog3*-expressing stage and maintain those phenotypes during the initial stages of *Ins2* expression in moving β-cells.

![Quantitative analysis of dynamic cell phenotypes. Single-cell resolution live cell imaging enables quantification of phenotypes including deformation and clustering. Shape factor, a measure of deformation, was calculated over time for a single β-cell (*A*) and a single *Neurog3*-tdTomato endocrine precursor (*B*). A shape factor value of one corresponds to a perfect circle, and a value of zero corresponds to a straight line. Integration of the single-cell shape factor curve (green lines in *A* and *B*) with respect to time provides the single-cell accumulated shape factor (scASF), a path-independent measurement corresponding to the amount of deformation undergone by a single cell (blue lines in *A* and *B*). *C*: Calculation of mean accumulated shape factors for the *Neurog3-*tdTomato and *Ins1-*GFP cell populations demonstrates no quantitative difference in deformation as observed by time-lapse microscopy. *D*: Calculation of the clustering index for the two cell populations indicates that the *Ins1-*GFP population tends to cluster more than the *Neurog3-*tdTomato population. Hrs, hours.](db150042f4){#F4}

To quantify *Neurog3-*tdTomato*^+^* and *Ins1*-GFP^+^ cell clustering in nascent islets, we adapted a clustering index previously used to assess pancreatic cell aggregation ([@B32]). This measurement calculates "object" size in image data: thus, assuming consistent cell size, increased object size corresponds to increased clustering of fetal islet cells. We normalized the clustering index to its value at *t* = 0 h for each time-lapse study to facilitate statistical comparisons of changes in clustering across multiple movies. We observed a transient decrease in the clustering index of *Neurog3*-tdTomato^+^ cells, consistent with the observation that these cells originate from fetal pancreatic epithelium and disperse during migration toward islet cell clusters ([Fig. 4*D*](#F4){ref-type="fig"}). By contrast, *Ins1*-GFP^+^ cell aggregation was reflected by a large increase in their clustering index (*P =* 0.03) ([Fig. 4*D*](#F4){ref-type="fig"}). These live-cell measurements should be useful for describing experimental alterations in islet cell migratory patterns and clustering, including the analysis of phenotypes in mutant pancreatic development (see below).

Neurog3 Is Required for Cell Shape Changes and Migration Into Nascent Islet Clusters {#s18}
------------------------------------------------------------------------------------

Prior studies suggest that *Neurog3* is required for the mobilization of islet progenitors from fetal epithelium, although the evidence for this has been indirectly inferred from fixed tissue analyses ([@B9],[@B26]). For example, lineage tracing of *Neurog3*-null cells suggests that these cells remain within the fetal pancreatic epithelium, where they redirect their fate toward ductal or acinar cell lineages ([@B13],[@B48]). To test directly the requirement for *Neurog3* in islet cell deformation and movement, we imaged *Neurog3^gfp/gfp^* organs at E13.5. In heterozygote controls, imaging revealed highly dynamic *Neurog3^gfp/+^* cells that deformed and extended processes, moved, and eventually clustered in nascent islets ([Fig. 5*A--C*](#F5){ref-type="fig"} and [Supplementary Movie 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). By contrast, homozygous *Neurog3^gfp/gfp^* cells failed to initiate movement and remained in epithelial tubes ([Fig. 5*D--F*](#F5){ref-type="fig"} and [Supplementary Movie 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Quantification of the shape factor for homozygous mutant *Neurog3^gfp/gfp^* cells revealed a significant reduction in cell deformation compared with control *Neurog3^gfp/+^* cells (*P* = 0.006) ([Fig. 5*G*](#F5){ref-type="fig"}). The lack of cell aggregation or islet differentiation in *Neurog3^gfp/gfp^* organs precluded quantification of clustering. Thus, single-cell imaging methods identified defects in pancreatic cell migration in mice lacking *Neurog3.*

![Time-lapse imaging of cells lacking *Neurog3* reveals a failure to undergo morphological changes and cell migration. *A*--*C*: Cells heterozygous for *Neurog3^gfp^* migrate and cluster, whereas *Neurog3^gfp/gfp^* cells (*D*--*F*) fail to leave epithelial tubules. *G*: A significant quantitative reduction in cell deformation was detected. *H*--*K*: Evaluation of the capacity for human *NEUROG3* alleles to induce islet cell deformation. Wild-type *NEUROG3* restores cell deformation and movement, *NEUROG3^R107S^* has a limited capacity for rescue and restores motility in only a few scattered cells, and *NEUROG3^P39X^* and *NEUROG3^N89D^* have no detectable effect on islet cell movement phenotypes. Scale bars: 100 μm. *P* value from Student *t* test.](db150042f5){#F5}

To test whether rescue of *Neurog3* mutant phenotypes by human *NEUROG3* alleles extended to live-cell deformation phenotypes, we generated time-lapse movies of *Neurog3^gfp/gfp^* organ rudiments injected with adenoviruses expressing human *NEUROG3* alleles. In contrast to Ad-RFP or Ad-NEUROG3^N89D^ injection, Ad-*NEUROG3* in *Neurog3^gfp/gfp^* organs restored cell movement, shape changes, and islet morphogenesis. Any GFP^high^ cells detected in *Neurog3^gfp/gfp^*;Ad-NEUROG3^R107S^ organs also underwent deformation, suggesting a binary output in which cells with high *Neurog3* activity undergo deformation, whereas cells with low *Neurog3* activity do not ([Fig. 5*H--K*](#F5){ref-type="fig"} and [Supplementary Movies 5--7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Consistent with the lack of activity detected for *NEUROG3^P39X^*, we did not detect GFP^high^ cells or cell deformation in *Neurog3^gfp/gfp^*;Ad-NEUROG3^P39X^ organs ([Fig. 5*J*](#F5){ref-type="fig"} and [Supplementary Movie 8](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1)). Together with molecular and immunohistological data above, these data provide evidence for rescue of multiple dynamic phenotypes by functional human *NEUROG3* alleles.

Discussion {#s19}
==========

Detailed assessment of cell and developmental phenotypes in normal and mutant living tissue provides powerful opportunities to understand gene function in organogenesis. Here, we describe a combination of fetal organ culture, live imaging, and genetic methods to dissect functions of *Neurog3*, a gene crucial for endocrine cell ontogeny and islet morphogenesis in the pancreas. By creating platforms for unique gene complementation and suppression studies in *Neurog3* mutant tissue, we evaluated the function of human disease-associated *Neurog3* mutations and assessed the capacity for *Neurog3*-independent islet differentiation. Quantification of dynamic cell phenotypes in distinct endocrine progeny with single-cell resolution in the fetal pancreas permitted us to measure and show that *Neurog3* is required for initiating multiple steps in islet morphogenesis, including cell deformation, movement, differentiation into hormone-expressing progeny, and cell aggregation to form nascent islets. The dissection of gene functions and cell dynamics using approaches detailed here should accelerate discovery of cell and genetic mechanisms underlying the mechanisms that coordinate islet formation.

Development of methods for transgenic alterations in cultured pancreatic tissue developing ex vivo permitted us to efficiently assess the capacity for patient-derived human alleles of *NEUROG3* to induce islet differentiation and formation. In these studies, we were able to study the activity of these alleles in a developmentally relevant context in pancreatic cells at an embryonic stage appropriate for *Neurog3* expression. Prior assessments of activity of these alleles has relied on in vitro assays in cell lines that are not known to have capacity for islet differentiation or on assays using chick embryonic models of endodermal development in *Neurog3* wild-type backgrounds ([@B14]--[@B17]). In these other systems, autoregulation by endogenous Neurog3 could complicate interpretation of results. By using embryonic *Neurog3*-null mouse pancreatic tissue and assessing multiple *Neurog3*-dependent phenotypes---including autoregulation, morphological changes, and activation of islet gene expression programs---we provide unique evidence that while at least one *NEUROG3* allele associated with enteric anendocrinosis is hypomorphic, the newly identified *NEUROG3^P39X^* allele has no detectable function and is likely a null allele.

The proband homozygous for the *NEUROG3^P39X^* allele did not develop neonatal insulin-dependent diabetes and had detectable serum C-peptide, suggesting β-cell development and function in this patient (M.G.M., unpublished observations). Thus, to the extent that *NEUROG3^P39X^* is a null allele, our studies raise the possibility that NEUROG3 function may not be required for β-cell development to the same degree as in mice, a possibility consistent with prior human studies ([@B14],[@B15]). In some vertebrates, including pigs and zebrafish, a clear ortholog of *NEUROG3* has not been identified. Thus, we speculate that other transcription factors could substitute for *Neurog3* in regulating islet cell development in human islet development, as is the case for *Ascl1b* and *Neurod1* in zebrafish ([@B49]). Consistent with this possibility, here we observed that *NEUROD1* overexpression was sufficient for partial bypass of the requirement for *Neurog3* in mouse islet development in cultured fetal pancreata. Establishment of *NEUROG3^P39X^* as a null allele suggests that a *NEUROG3*-independent gene network may permit formation of a limited population of islet cells in human development.

The gene delivery methods described here should enable testing of genetic hypotheses using gain-of-function methods, including dissection of pathways regulating islet differentiation downstream of *Neurog3*. For example, delivery of direct *Neurog3* target genes including *NeuroD1* was sufficient to restore some islet differentiation in *Neurog3*-null pancreas. Without using in vitro gene delivery methods, similar genetic suppression experiments might require generation of multiple new mouse transgenic or knock-in lines. In addition, we demonstrate that similar viral methods could be applied to analyze human pancreatic development, enabling future studies relevant to human biology. We recognize limitations to viral expression of transgenes, which may include failure to appropriately regulate transcript levels and background labeling of nonepithelial cell types. In principle, these approaches permitting genetic complementation should be readily adaptable to study the activity of other genes and alleles in pancreas development or any other fetal organ accessible to in vitro culture and viral gene transduction.

Dual-color confocal imaging permitted assessment of transient or dynamic phenotypes like cell deformation and movement across multiple stages of islet development. Compared with prior efforts at live cell analysis ([@B32],[@B47],[@B50]), we present data using single cells from multiple cell populations tracked simultaneously. These studies demonstrate the capacity for directly observing differentiation and tracking morphological dynamics of single cells. The cell shape changes and cellular extensions observed in our video data were not detected in fixed sections, possibly reflecting limitations of histological approaches to preserve fine or transient subcellular morphologies ([@B51]). Applying quantitative methods, we described the maintenance of migratory phenotypes as islet cells differentiate from hormone-negative endocrine precursors into hormone-expressing fetal β-cells. Thus, our work provides a foundation for analysis of disrupted islet cell development and morphogenesis in mutant pancreatic development.

To develop methods for genetic studies of living tissue, we analyzed *Neurog3* mutants---which have severe disruptions of cell movement and clustering---and optimized methods for quantifying and analyzing these phenotypes. Although indirect evidence suggested that *Neurog3* controls the acquisition of cell deformation or migratory phenotypes ([@B9],[@B48]), here we have provided direct evidence for a failure by islet progenitor cells to initiate cell shape changes or movement in the absence of Neurog3. Future experiments could dissect whether acquisition of migratory phenotypes is invariably linked to islet differentiation or whether one process could occur in the absence of the other. We also applied live-imaging methods to visualize directly the failure of pancreatic cells to elevate *Neurog3* promoter activity in *Neurog3* knockout cells, corroborating prior findings supporting a positive autoregulatory loop driving fetal pancreatic *Neurog3* expression ([@B38]). Consistent with the results from our genetic complementation experiments, we found that *NEUROG3* alleles could restore morphogenetic movements, with the number of motile cells observed in each organ rudiment proportional to allele strength. Overall, the imaging methods we have developed could allow tracking of the behavior of multiple cell populations in the context of genetic or chemical interventions in pancreatic development.

In summary, we have assessed human allele function in a developmentally relevant context, evaluated the capacity for *Neurog3* targets to restore islet differentiation in the absence of *Neurog3*, and measured live cell phenotypes in normal and mutant islet development. The methods described here should be useful for dissecting genetic networks and cell biological events controlling pancreatic islet development.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0042/-/DC1>.
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